Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
(ES)
Source
CIMA_ES
(
ARTG
)
IMBRUVICA is indicated for the treatment of patients with MCL who have received at least one prior therapy.,IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenströms macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with Waldenstroms macroglobulinaemia (WM).,IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).,IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior therapy.
